Renaissance Technologies LLC Buys Shares of 22,931 SAGE Therapeutics Inc (SAGE)

Renaissance Technologies LLC bought a new stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 22,931 shares of the biopharmaceutical company’s stock, valued at approximately $3,777,000. Renaissance Technologies LLC owned about 0.05% of SAGE Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. BlackRock Inc. raised its position in shares of SAGE Therapeutics by 16.4% during the 4th quarter. BlackRock Inc. now owns 3,444,171 shares of the biopharmaceutical company’s stock valued at $567,290,000 after acquiring an additional 486,135 shares during the last quarter. Carillon Tower Advisers Inc. bought a new stake in shares of SAGE Therapeutics during the 4th quarter valued at $74,300,000. Geode Capital Management LLC raised its position in shares of SAGE Therapeutics by 23.6% during the 4th quarter. Geode Capital Management LLC now owns 380,896 shares of the biopharmaceutical company’s stock valued at $62,737,000 after acquiring an additional 72,790 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of SAGE Therapeutics by 25.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 189,230 shares of the biopharmaceutical company’s stock valued at $31,169,000 after acquiring an additional 38,204 shares during the last quarter. Finally, Emerald Advisers Inc. PA raised its position in shares of SAGE Therapeutics by 123.0% during the 4th quarter. Emerald Advisers Inc. PA now owns 168,785 shares of the biopharmaceutical company’s stock valued at $27,801,000 after acquiring an additional 93,106 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

How to Become a New Pot Stock Millionaire

SAGE has been the subject of several recent research reports. JPMorgan Chase reiterated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, January 10th. BidaskClub upgraded shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. Needham & Company LLC reiterated a “buy” rating and set a $193.00 target price on shares of SAGE Therapeutics in a research report on Friday, February 23rd. Morgan Stanley initiated coverage on shares of SAGE Therapeutics in a research report on Monday, February 26th. They set an “overweight” rating and a $225.00 target price for the company. Finally, SunTrust Banks upped their target price on shares of SAGE Therapeutics to $203.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $185.20.



SAGE opened at $148.01 on Friday. SAGE Therapeutics Inc has a 12 month low of $59.57 and a 12 month high of $195.97. The firm has a market capitalization of $7,893.95, a P/E ratio of -20.88 and a beta of 3.03.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.23. During the same quarter in the prior year, the firm posted ($1.50) earnings per share. research analysts expect that SAGE Therapeutics Inc will post -8.31 earnings per share for the current year.

In related news, Director Steven M. Paul sold 58,139 shares of the company’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $172.00, for a total value of $9,999,908.00. Following the completion of the transaction, the director now directly owns 632,712 shares of the company’s stock, valued at approximately $108,826,464. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kevin P. Starr sold 59,000 shares of the company’s stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $168.85, for a total transaction of $9,962,150.00. Following the completion of the transaction, the director now directly owns 326,817 shares of the company’s stock, valued at $55,183,050.45. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/04/21/renaissance-technologies-llc-buys-shares-of-22931-sage-therapeutics-inc-sage.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply